PharmaLogic, a CDMO and radiopharmaceutical services provider, has opened its radiopharmaceutical production and research facility in Los Angeles, CA. Acquired in 2022, PharmaLogic has made significant investments in the facility with extensive renovations and state-of-the-art equipment for the development of radiopharmaceuticals in the region.
 
The renovated production and lab space will enable PharmaLogic to scale up current production, as well as channel significant resources towards the research and development of new radiopharmaceuticals.
 
“We’re thrilled to unveil our new cyclotron facility,” said Steve Chilinski, CEO of PharmaLogic. “Being in Los Angeles enables us to collaborate with leading healthcare providers and researchers promoting the development of novel radiopharmaceuticals and expanding patient access to exciting new radiopharmaceutical diagnostics.”